Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
The phase II Study is to explore the efficacy and safety of Tislelizumab as consolidation therapy in patients with locally advanced non-small cell lung cancer who have not progressed following neoadjuvant chemotherapy plus Tislelizumab ± Bevacizumab and definitive concurrent chemoradiation therapy.
Stage III Non-small Cell Lung Cancer
DRUG: Neoadjuvant chemo-immunotherapy|DRUG: Bevacizumab|RADIATION: Radiotherapy|DRUG: Tislelizumab
Progression free survival, From the start date of initial treatment to progression, death or last follow-up., 2-year
Overall survival, From the start date of initial treatment to death or to last follow-up., 2-year|Adverse Event, Toxicities were evaluated using the CTCAE 5.0, 2-year|Health-related Quality of Life, An individual's or perceived physical and mental health during and after treatment., 2-year|Objective response rate, Tumor response to neoadjuvant immuno-chemotherapy and radiotherapy based on RECIST 1.1, 2-year
The phase II Study is to explore the efficacy and safety of Tislelizumab as consolidation therapy in patients with locally advanced non-small cell lung cancer who have not progressed following neoadjuvant chemotherapy plus Tislelizumab ± Bevacizumab and definitive concurrent chemoradiation therapy.